title: Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
abstract: To clarify cellular biological varieties of myeloma cells, biological differences were analyzed between 2 human myeloma cell lines, KMS-12-PE and KMS-12-BM, derived from pleural effusion and bone marrow, respectively, of a single patient. Although both lines were considered to be derived from the same clone because both had the same chromosomal marker and immunoglobulin H rearrangement, several biological differences were noted. CD11a and CD20 were highly expressed in the KMS-12-BM line, whereas the KMS-12-PE line showed a higher expression of CD7 and CD95/Fas. Although growth was stimulated in KMS-12-BM by interleukin-6 and interferon-alpha, it was inhibited in KMS-12-PE. In addition, apoptosis inhibitors Bcl-2 and Bcl-X(L) were highly expressed in KMS-12-BM cells. Because KMS-12-PE was cultivated 2 months before KMS-12-BM, these differences might be related to their origin (pleural effusion and bone marrow) or the phases of disease progression. However, these biological differences may help clarify myeloma cell biology and lead to improvement in treatment for myeloma patients.
authors.affiliation: Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama, Japan. takemi@med.kawasaki-m.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Otsuki
authors.forename: H
authors.initials: H
authors.lastname: Hata
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: H
authors.initials: H
authors.lastname: Matsuzaki
authors.forename: K
authors.initials: K
authors.lastname: Yata
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Yawata
authors.forename: A
authors.initials: A
authors.lastname: Ueki
authors.forename: O
authors.initials: O
authors.lastname: Yamada
mesh_terms: D000954:Antigens, Surface / Q000032:analysis; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D015153:Blotting, Western; D001853:Bone Marrow; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D007564:Japan; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D010996:Pleural Effusion; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000378:metabolism
chemical_list: D000954:Antigens, Surface; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D015850:Interleukin-6; D019253:Proto-Oncogene Proteins c-bcl-2; D005047:Etoposide; D007371:Interferon-gamma; D008558:Melphalan